目的 建立左甲狀腺素鈉片藥物利用評(píng)價(jià)細(xì)則，探討AHM賦權(quán)聯(lián)合TOPSIS法在左甲狀腺素鈉片藥物利用合理性評(píng)價(jià)中的應(yīng)用。方法 制定左甲狀腺素鈉片藥物利用評(píng)價(jià)標(biāo)準(zhǔn)，采用層次分析-逼近理想解排序（AHP-TOPSIS）法，對(duì)寧德師范學(xué)院附屬寧德市醫(yī)院2021年1月—2023年3月使用左甲狀腺素鈉片患者的用藥合理性進(jìn)行評(píng)價(jià)。結(jié)果 共抽取276份病歷，其中相對(duì)接近度（C_i）≥90%的占0.36%（1份），80%≤C_i＜90%的占10.14%（28份），70%≤C_i＜80%的占17.75%（49份），60%≤C_i＜70%的占51.09%（141份），50%≤C_i＜60%的占18.12%（50份），C_i＜50%的占2.54%（7份）。左甲狀腺素鈉片不合理用藥主要體現(xiàn)在給藥時(shí)間間隔、給藥時(shí)間、實(shí)驗(yàn)室檢查、給藥劑量、適應(yīng)證等方面。結(jié)論 通過(guò)AHM-TOPSIS建立了左甲狀腺素鈉片臨床應(yīng)用合理性評(píng)價(jià)方法，所建立的方法切實(shí)可行。

Objective To establish thedetailed rules for evaluating drug utilization of levothyroxine sodium tablets by AHM-TOPSIS method to provide references for its clinical rational application. Methods Establishing the drug utilization review standard of levothyroxine sodium tablets. According to this standard rules to analyze and evaluate the rationality of 276 prescriptions with levothyroxine sodium tablets from Jan. 2021 to Mar. 2023 by AHP-TOPSIS method. Results Among 276 medical records evaluated by levothyroxine sodium tablets. There were 1 cases (0.36%) with C_i ≥ 90%, 28 cases (10.14%) with C_i 80% — 90%, 49 cases (17.75%) with C_i 70% — 80%, 141 cases (51.09%) with C_i 60% — 70%, 50 cases (18.12%) with C_i 50% — 60%, and 7 case (2.54%) with C_i < 50%. The irrational use of levothyroxine sodium tablets was mainly reflected in aspects such as administration time interval, administration time, laboratory examination, dosage, indications, and indications. Conclusion The rationality evaluation method of clinical application of levothyroxine sodium tablets is established by AHM-TOPSIS method, and the method is feasible.

R977

福建省科技廳引導(dǎo)性項(xiàng)目（2018Y0047）